Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd.

Overview
Date Founded

1994

Headquarters

10 Bareket Street,Kiryat Matalon,Petach Tikva, HaMerkaz 49170

Type of Company

Public

Employees (Worldwide)

8

Industries

Biotechnology
Pharmaceuticals

Company Description

Can-Fite BioPharma Ltd. engages in the development of drugs for cancer and inflammatory diseases. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.

Executives & Employees

Founder

Chief Financial & Operating Officer

Director-Regulatory & Clinical Operations

Medical Director

Vice President-Drug Development

Vice President, Business Development

Co-Founder

Board of Directors

Co-Founder at Can-Fite BioPharma Ltd.

Director & Chief Executive Officer at Gaon Group Ltd.

Founder at Can-Fite BioPharma Ltd.

Chief Executive Officer & Director at Maanit-Goldman Management & Investments (2002) Ltd.

Fellow at The Royal Society of Medicine

Executive Director-Strategic Initiatives at MATIMOP

Paths to Can-Fite BioPharma Ltd.
Potential Connections via
Relationship Science
You
Can-Fite BioPharma Ltd.
Recent Transactions
Details Hidden

Can-Fite BioPharma Ltd. raised money in a private placement transaction

Details Hidden

Can-Fite BioPharma Ltd. raised money in a private placement transaction

Details Hidden

Can-Fite BioPharma Ltd. raised money in a private placement transaction

Transaction Advisors
Investment Advisor

Advised onCan-Fite BioPharma Ltd. raised money in a private placement transaction

Investment Advisor

Advised onCan-Fite BioPharma Ltd. raised money in a private placement transaction

Clients

China Medical System Holdings Limited (“CMS”, together with its subsidiaries, the "Group") is a pharmaceutical services provider based in China, focusing on marketing promotion and sales of prescription drugs to all therapeutic departments in hospitals. The Group was established in 1995, and was listed on AIM in London (ticker: CMSH) in June 2007, the Group was listed on Main Board Market in Hong Kong on 28 September 2010 while it was delisted on AIM at the same time. The Group follows two business models which can be commonly found in the pharmaceutical industry in China, the Direct Academic Orientated Promotion Model and Agency Promotion Model, and with two distinct third party promotion networks, the Direct Academic Orientated Promotion Network (the “Direct Network”) and the Agency Promotion Network (the “Agency Network”), both of which hold leading positions in the Chinese market. On the 3 April 2011, the Group successfully acquired Great Move Enterprise Limited (“Great Move”) and its subsidiaries, the main wholly subsidiary of Great Move is Tianjin Precede Medical Trade Development Co., Ltd.(which has been officially renamed Tianjin Kangzhe Pharmaceutical Technology Development Co., Ltd.on 24 October 2011), which mainly engages in the marketing, promotion and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies via Agency Network in China. After the acquisition, the Group` business model evolved from simply depending on internal marketing and promotion team to promote and sell products directly to physicians (Direct Academic Orientated Promotion Model) to a new integrated development model that incorporates the independent third party sales representatives and distributors to sale and promote products (Agency Promotion Model) in China. On the 31 May 2011, the Group successfully acquired 51% equity interests of Guangming Pharmaceutical Co., Ltd. (which has been officially renamed Guangxi Kangzhe Guangming Pharmaceutical Co., Ltd. on 10 October 2011) via cash investment for capital and stock increase to gain the permanent China market rights of a type of enteral nutrition drug-“Protein Hydrolysate”. The speedy introduction of this product is the result of the combination of the professional academic ability from our Direct Network and the rapid market coverage ability of our Agency Network. We introduce drugs that prove to be competitive and focus on providing marketing, promotion and sales services to specialty pharmaceutical companies by leveraging our successful product selection system and the insights in Chinese pharmaceutical market. As at 31 December 2011, the Direct Network of the Group had close to 1,200 sales, marketing and promotion professionals; the Agency Network had close to 1,000 independent third party sales representatives or distributors and around a hundred of senior regional and marketing managers. The Group`s sales coverage spanned over 14,600 hospitals throughout China, of which almost 8,600 hospitals were covered by the Direct Network and over 7,800 hospitals were covered by the Agency Network. The Group follows a market-oriented product selection strategy and introduces prescription drugs with high growth potential under its Direct Academic Orientated Promotion Model. We formulate appropriate marketing strategies for each drug, leveraging the insights in the Chinese pharmaceutical market, prevailing treatment protocols of physicians, demographic profile of the relevant patient pool in China and potential competitive advantages of drugs. Meanwhile, in order to help drive demand for pharmaceutical products, our professional, stable and experienced marketing, promotion and sales team conducts various physician-oriented academic promotion activities such as one-on-one physician visits, medical symposia and industry conferences, and via our proprietary information management system to keep track of these activities and review operations in a timely manner, enabling us to manage our overall business effectively and efficiently. In addition, the Group also provides other ancillary services needed by pharmaceutical companies to introduce their products to China, including handling product registration, clinical trials, and bidding in collective tender processes. With appropriate product positioning, strategic planning and execution, the Group gained remarkable performance. From 2007 to 2011, the compound annual growth rate (CAGR) of revenue was 42.0%, and the CAGR of net profit achieved 63.7%. We also received a number of recognitions, including the Group was ranked in the list of Forbes “Asia’s Best 200 Enterprises Under a Billion” in 2008 and “Top 100 Enterprises in Shenzhen” in 2009, 2010 and 2011, and we also gained Forbes “China’s Best Up-and-Coming Business” three times in 2010, 2011 and 2012. As a leading China-based pharmaceutical services company, the Group established long-term business partnership with specialty pharmaceutical companies from Germany, Denmark, Ireland, France, Ukraine, Japan and China. We will continuously introduce new products and extend marketing, promotion and sales network to strengthen our leading position in Chinese pharmaceutical service market, and through the professional and quality service to catch opportunities from the enormous growth of Chinese pharmaceutical market and strives to become the preferred partner for overseas and domestic pharmaceutical companies who target at Chinese market.

Chong Kun Dang Pharmaceutical Corp. engages in the manufacture, distribution, research, and development of pharmaceuticals. Its products include medicine for antidiabetic, antivirus, beta-blocking, anti-hyperlipidemia and others. The company was founded on November 5, 2013 and is headquartered in Seoul, South Korea.

ChongKunDang Holdings Corp. is a business development and investment company, which focuses on pharmaceutical operations. Through its subsidiaries, it also engages in the following activities; real estate leasing, engineering and construction, outsourcing and transportation, advertisement, finance, and information technology. The company was founded on May 7, 1941 and is headquartered in Seoul, South Korea.

Key Stats and Financials As of 2019
Market Capitalization
$29.3M
Total Enterprise Value
$6.12M
Earnings Per Share
$-0.11
Enterprise Value / Sales
3.16x
TEVNet Income
-0.67x
Debt TEV
0.01x
EBITDAMargin
-588.63%
Three Year Compounded Annual Growth Rate Of Revenue
123.1%
Revenue
$1.94M
Total Debt
$69.3K
Total Equity
$811K
Net Profit
$-9.14M
EBITDA
$-11.4M
Suppliers
University of Leiden Leiden, Netherlands

Leiden University (Dutch: Universiteit Leiden), located in the city of Leiden, is the oldest university in the Netherlands.[4] The university was founded in 1575 by William, Prince of Orange, leader of the Dutch Revolt in the Eighty Years' War. The Dutch Royal Family and Leiden University still have a close relationship; Queens Juliana and Beatrix and King Willem-Alexander are all former students. Leiden University has six faculties, over 50 departments and enjoys an outstanding international reputation. In 2013 Leiden was the highest ranked university in the Netherlands in the Times Higher Education World University Rankings, where it was rated as the 64th best university worldwide and 61st for international reputation. Shanghai Jiao Tong University's 2011 Academic Ranking of World Universities ranked Leiden University as the 65th best university worldwide.[5] The Times Higher Education World University Rankings consistently rank Leiden University as the best university in Continental Europe for Arts and Humanities. The University is associated with ten leaders and Prime Ministers of the Netherlands including the current Prime Minister Mark Rutte, nine foreign leaders, among them the 6th President of the United States John Quincy Adams, two Secretary Generals of NATO, a President of the International Court of Justice and sixteen recipients of the Nobel Prize (including renowned physicists Albert Einstein and Enrico Fermi). The university came into particular prominence during the Dutch Golden Age, when scholars from around Europe were attracted to the Dutch Republic due to its climate of intellectual tolerance and Leiden's international reputation. During this time Leiden was home to such figures as René Descartes, Rembrandt, Hugo Grotius, Baruch Spinoza and Baron d'Holbach. The university is a member of the Coimbra Group, the Europaeum and the League of European Research Universities. Albert Einstein was known as a professor at Leiden University. Einstein regularly taught Leiden students for a few weeks per year. His first lecture at Leiden was about "Ether and Relativity Theory".[6] Leiden University houses more than 40 national and international research institutes.

Univo Pharmaceuticals Ltd. Biotechnology | Tel Aviv, Israel

Univo Pharmaceuticals Ltd. engages in the development, manufacture, and supply of cannabis products. Its products include dried flowers and extracts. The company was founded by Alexander Kozak, Golan Bitton, Nir Ben Zvi, and Max Herzberg on April 4, 1993 and is headquartered in Tel Aviv, Israel.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Exelixis, Inc. Biotechnology - South San Francisco, CA

Exelixis is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer. In advancing our first product, COMETRIQ, from discovery to market, we have established an effective and integrated infrastructure that encompasses the entire biopharmaceutical development continuum. We are committed to excellence in all aspects of our work and are dedicated to improving the care and outcome of cancer patients.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Can-Fite BioPharma Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Can-Fite BioPharma Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Can-Fite BioPharma Ltd..